2022 What's Next for Asia-Pacific Tumor Markers Testing Market High-Growth Opportunities for Cancer Diagnostic Tests and Analyzers?-An 18-Country Analysis-Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

August 2022 | | ID: 2820B60A145AEN
Venture Planning Group

Abstracts

The report is available in Local PDF, Global PDF, and Data Pack formats (supplier shares, test volumes, sales forecasts). The report is delivered in both Excel and PDF.

This new 18-country report from LeadingMarketResearch.com is available by country, market segment, section, or individual test.

The report is available by section, and can be customized to specific information needs and budget.

This report is designed to assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding cancer diagnostic testing market, in evaluating emerging opportunities and developing effective business strategies during the next five years.

The report provides granular market segmentation analysis and forecasts for over 40 tumor markers; profiles leading suppliers and recent market entrants with innovative technologies and products; reviews current and emerging assays; reviews current instrumentation; evaluates emerging technologies; and offers specific opportunities and growth strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Country Analyses

Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand, Turkey, Vietnam

Business Opportunities and Strategic Recommendations

• Specific new product development opportunities with potentially significant market appeal during the next five years.
• Design criteria for new products.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Tests

• Oncogenes - Biochemical Markers - Growth Factors - Colony Stimulating Factors - Hormones - Immunohistochemical Stains - Lymphokines
• ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

• Sales and market shares of major cancer diagnostic product suppliers in major countries by individual test.
• Five-year test volume and sales forecasts for major cancer diagnostic assays.

Instrumentation Review

Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

• Assessment of latest technologies and their potential applications for cancer diagnostic testing.
• Review of competing/complementing technologies.
• Companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Strategies

Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Contents

I. INTRODUCTION

II. WORLDWIDE MARKET OVERVIEW

III. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Reagent Kits and Test Systems/Panels
B. Instrumentation
C. Computers, Software and Automation
D. Auxiliary Products

IV. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

V. ALTERNATIVE MARKET PENETRATION STRATEGIES

A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies

VI. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges

VII. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

A. Cancer Statistics and Etiology
  1. Breast Cancer
  2. Lung Cancer
  3. Colon and Rectum Cancer
  4. Prostate Cancer
  5. Stomach Cancer
  6. Leukemia
  7. Lymphoma
  8. Oral Cancer
  9. Skin Cancer
  10. Uterine Cancer
  11. Ovarian Cancer
  12. Bladder Cancer
B. Major Current and Emerging Cancer Diagnostic Tests
  1. Introduction
  2. Tumor Marker Classification
  3. ACTH
  4. Alpha-Fetoprotein (AFP)
  5. Beta-2 Microglobulin
  6. CA 15-3/27.
  7. CA 19-9
  8. CA-125
  9. Calcitonin
  10. Carcinoembrionic Antigen (CEA)
  11. Estrogen and Progesterone Receptors
  12. Ferritin
  13. Gastrin
  14. Human Chorionic Gonadotropin (HCG)
  15. Insulin
  16. NSE
  17. Occult Blood
  18. PAP Smear/HPV
  19. Prostatic Acid Phosphatase (PAP)
  20. Prostate-Specific Antigen (PSA)
  21. Squamous Cell Carcinoma Antigen (SCC)
  22. T and B Lymphocytes
  23. TdT
  24. Thyroglobulin
  25. Tissue Polypeptide Antigen (TPA)
  26. Biochemical Tumor Markers
  27. Oncogenes
      Abl/abl-bcr
      AIB1
      BCL-2
      BRCA1
      CD44
      C-fos
      C-myb
      C-myc
      CYP-17
      Erb-B
      HPC1
      N-myc
      P40
      P51
      P53
      PIK3CA
      PTI-1
      Ras
      Reg
      Sis
      Src and others
  28. Polypeptide Growth Factors
      Basic Fibroblast Growth Factor
      Beta-TGF
      Cachectin (TNT)
      Calmodulin
      ECFR
      Nerve Growth Factor (NGF)
      Epidermal Growth Factor (EGF)
      Ornithine Decarboxylase
      Transferrin
      Transforming Growth Factor-Alpha
  29. Ectopic Hormones
  30. Colony Stimulating Factors
  31. Lymphokines
      Alpha-Interferon
      B Cell Growth Factors
      B Cell Growth Factor (BCGF)
      Gamma-Interferon
      Interleukin-1 (IL-1)
      Macrophage Activating Factor
  32. Immunohistochemical Stains
  33. Emerging Tumor Markers
      N-Acetylglucosamine
      Actin
      Alpha-Actin
      Antineuronal Antibodies
      7B2
      B7  2.
      Bax
      BCD-F9
      BLCA-4
      Blood Group Antigens A,B,H
      CA
      CA 72-4/TAG-72
      CA
      CA-242
      CA-549
      CAM
      CAR-3
      Cathepsin-D
      Chromogranin A and B
      Cluster 1 Antigen
      Cluster-5/5A Antigen
      CTA
      CU18
      DR-70
      DU-PAN-2
      Endometrial Bleeding Associated Factor       Endostatin
      Epithelial Membrane Antigen
      Feulgen Hydrolysis
      Fibronectin
      FSH
      (1->3)-L-fucosyltransferase
      Gastrin-Releasing Peptide (GRP)
      GDCFP-15
      Glucagon
      Glycoamines
      H23
      Her-2
      Human Carcinoma Antigen
      HPA
      HSP27
      Intermediate Filaments
      Cytokeratins/CK18/Cyfra 21-1
      Desmin
      Gliofibrillary Acid Protein
      Neurofilaments
      Vimentin
      KA
      Kinases
      KP16D3
      LAI
      Leukocyte Common Antigen
      Lewis Antigens
      Lysophosphatidic Acid (LPA)
      Ma 695/Ma
      MABDF3
      MAG
      ME1
      Minactivin
      MN/CA9
      MSA
      Mucin Cancer Antigen (MCA)
      Multiple Tumor Suppressor
      Myosin
      NEA-130
      NMP22
      OA-519
      Opioid Peptides
      P-glycoprotein
      Pancreatic Oncofetal Antigen (POA)
      Placental Lactogen
      PR92
      Proliferative Index, Ki-67
      Px
      RB Inactivation/Deletion
      Ret
      SCCL
      Selectin
      Sialic Acid
      Sialyl SSEA-1/SLX
      SN10
      Somatostatin
      TA-90
      TABA
      Tachykinin
      TAG
      TPS
      Troponin
      Tubulin
      VCAM
      VEGF
      Villen and others
C. Cancer Diagnostic Testing Instrumentation Review and Market Needs
D. Current and Emerging Cancer Diagnostic Technologies
  1. Monoclonal and Polyclonal Antibodies
  2. Immunoassays
  3. Molecular Diagnostics
  4. Chromosome Analysis
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. Artificial Intelligence
  6. Flow Cytometry
  7. Two Dimensional Gel Electrophoresis (2-DGE)
  8. Biosensors
  9. Competing/Complementing Technologies
E. Personal Testing

VIII. COUNTRY MARKET ANALYSES: TEST VOLUME AND SALES FORECASTS, SUPPLIER SHARES

Australia
Bangladesh
China
Hong Kong
India
Indonesia
Japan
Malaysia
Myanmar
New Zealand
Pakistan
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam

IX. COMPETITIVE PROFILES

The report provides strategic assessments of over 30 leading cancer diagnostics market players and start-up companies with innovative technologies and products, including:
      Abbott
      Affymetrix
      Beckman Coulter/Danaher
      Becton Dickinson
      bioMerieux
      Bio-Rad
      Cepheid
      DiaSorin
      Eiken Chemical
      Elitech Group
      Enzo Biochem
      Fujirebio
      Grifols
      Hologic
      Leica Biosystems
      Ortho-Clinical Diagnostics
      PerkinElmer
      Qiagen
      Roche
      Siemens Healthineers
      Takara Bio
      Thermo Fisher
      Wako and others.

List Of Tables

LIST OF TABLES

Australia Cancer Diagnostic Volume Forecasts by Test
Australia Cancer Diagnostics Sales Forecasts by Test
Bangladesh Cancer Diagnostic Volume Forecasts by Test
Bangladesh Cancer Diagnostics Sales Forecasts by Test
China Cancer Diagnostic Volume Forecasts by Test
China Cancer Diagnostics Sales Forecasts by Test
Hong Kong Cancer Diagnostic Volume Forecasts by Test
Hong Kong Cancer Diagnostics Sales Forecasts by Test
India Cancer Diagnostic Volume Forecasts by Test
India Cancer Diagnostics Sales Forecasts by Test
Indonesia Cancer Diagnostic Volume Forecasts by Test
Indonesia Cancer Diagnostics Sales Forecasts by Test
Japan Executive Summary Table: Total Tumor Marker Test Volume and Sales Forecast by Market Segment
Japan, Estimated Cancer Death Rates
Per 100,000 Population
Japan, Laboratories Performing Tumor Marker Tests by Market Segment
Japan, Hospital Laboratories Performing
Tumor Marker Tests by Bed Size
Japan, Commercial/Private Laboratories
Performing Tumor Marker Tests by Annual Test Volume
Japan, Total Tumor Marker Testing Volume Forecast by Market Segment
Japan, All Market Segments Major Tumor Marker Test Volume Forecast
Japan, Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
Japan, Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
Japan, Total Tumor Marker Sales Forecast by Market Segment
Japan, All Market Segments Major Tumor Marker Sales Forecast by Test
Japan, Hospital Laboratories Major Tumor Marker Sales Forecast by Test
Japan, Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
Japan, ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, AFP Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Beta-2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, CA 15-3/27. 29 Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, CEA Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Colon-Specific Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, HCG Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Interferons Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Interleukins Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, NSE Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Pancreatic Oncofetal Antigen Test Volume and Diagnostics
Japan, PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, PAP Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, PSA Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, TDT Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, TPA, Test Volume and Diagnostics Sales Forecast by Market Segment
Japan, Total Tumor Marker Sales by Major Suppliers
Japan, AFP Testing Market Diagnostics Sales by Major Supplier
Japan, CA 15-3/27. 29 Testing Market Diagnostics Sales by Major Supplier
Japan, CA 19-9 Testing Market Diagnostics Sales by Major Supplier
Japan, CA 125 Testing Market Diagnostics Sales by Major Supplier
Japan, Calcitonin Testing Market Diagnostics Sales by Major Supplier
Japan, PAP Testing Market Diagnostics Sales by Major Supplier
Japan, PSA Testing Market Diagnostics Sales by Major Supplier
Malaysia Cancer Diagnostic Volume Forecasts by Test
Malaysia Cancer Diagnostics Sales Forecasts by Test
Myanmar Cancer Diagnostic Volume Forecasts by Test
Myanmar Cancer Diagnostics Sales Forecasts by Test
New Zealand Cancer Diagnostic Volume Forecasts by Test
New Zealand Cancer Diagnostics Sales Forecasts by Test
Pakistan Cancer Diagnostic Volume Forecasts by Test
Pakistan Cancer Diagnostics Sales Forecasts by Test
Philippines Cancer Diagnostic Volume Forecasts by Test
Philippines Cancer Diagnostic Volume Forecasts by Test
Singapore Cancer Diagnostic Volume Forecasts by Test
Singapore Cancer Diagnostics Sales Forecasts by Test
South Korea Cancer Diagnostic Volume Forecasts by Test
South Korea Cancer Diagnostics Sales Forecasts by Test
Taiwan Cancer Diagnostic Volume Forecasts by Test
Taiwan Cancer Diagnostics Sales Forecasts by Test
Thailand Cancer Diagnostic Volume Forecasts by Test
Thailand Cancer Diagnostics Sales Forecasts by Test
Vietnam Cancer Diagnostic Volume Forecasts by Test
Vietnam Cancer Diagnostics Sales Forecasts by Test
Tumor Marker Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta-2 Microglobulin Tests
Major Companies Developing or Marketing CA 15-3/27. 29 Tests
Major Companies Developing or Marketing CA 19-9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications In Cancer Diagnosis
Oncogenes Potential Applications In Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications In Cancer Diagnosis
Colony Stimulating Factors Potential Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
Immunohistochemical Stains Potential Applications in Cancer Diagnosis